24 results for "Adam Mor"
Showing 1–20 · 0.55 seconds · RSS
-
Journal Article
Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1
The emergence of anti–cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4), anti–programmed cell death 1 ligand (anti–PD-1), and anti–PD-L1 antibodies as immune checkpoint inhibitors (ICIs) revolutionized the treatment of numerous types of tumors. These antibodies, both alone and in combination, provide…
-
Journal Article
SLAM Associated Protein Signaling in T Cells: Tilting the Balance Toward Autoimmunity
T cell activation is the result of the integration of signals across the T cell receptor and adjacent co-receptors. The signaling lymphocyte activation molecules (SLAM) family are transmembrane co-receptors that modulate antigen driven T cell responses. Signal transduction downstream of the SLAM…
-
Journal Article
Combination Approaches to Target PD-1 Signaling in Cancer
Cancer remains the second leading cause of death in the US, accounting for 25% of all deaths nationwide. Immunotherapy techniques bolster the immune cells’ ability to target malignant cancer cells and have brought immense improvements in the field of cancer treatments. One important inhibitory…
-
Journal Article
Immunohistochemistry of Immune Cells and Cells Bound to in vivo Administered Antibodies in Liver, Lung, Pancreas, and Colon of B6/lpr Mice
Employing a novel mouse model of immune related adverse events (irAEs) induced by combination of anti-PD1 and anti-CTLA-4 antibodies, we visualized immune infiltration into the liver, lung, pancreas, and colon. Here, we describe the avidin-biotin conjugate (ABC) method used to stain T cells (CD4…
-
Journal Article
Data on the identification of VRK2 as a mediator of PD-1 function
Therapeutic programmed cell death protein 1 (PD-1) blockade enhances T cell mediated anti-tumor immunity, but many patients do not respond, and a significant proportion develops inflammatory toxicities. To develop better therapeutics and to understand the signaling pathways downstream of PD-1 we…
-
Journal Article
An Imaging-Based Assay to Measure the Location of PD-1 at the Immune Synapse for Testing the Binding Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies
PD-1 is an immune checkpoint on T cells. Antibodies to PD-1 or its ligand PD-L1 are gaining popularity as a leading immunotherapy approach. In the US, 40% of all cancer patients will be treated with anti-PD-1 or anti-PD-L1 antibodies but, unfortunately, only 30% will respond, and many will develop…
-
Journal Article
SAP-expressing T peripheral helper cells identify systemic lupus erythematosus patients with lupus nephritis
IntroductionT follicular (TFH) and peripheral helper (TPH) cells have been increasingly recognized as a pathogenic subset of CD4 T cells in systemic lupus erythematosus (SLE). The SLAM Associated Protein (SAP) regulates TFH and TPH function by binding to the co-stimulatory signaling lymphocyte…
-
Journal Article Full text
A novel mouse model for checkpoint inhibitor-induced adverse events.
Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of a variety of cancers, however their therapeutic potential is limited by abstruse immune related adverse events. Currently, no robust animal model exists of checkpoint inhibitor-induced adverse events…
Also available at: PLOS
-
Journal Article Full text
Structure-function analysis of nucleolin and ErbB receptors interactions.
BackgroundThe ErbB receptor tyrosine kinases and nucleolin are major contributors to malignant transformation. Recently we have found that cell-surface ErbB receptors interact with nucleolin via their cytoplasmic tail. Overexpression of ErbB1 and nucleolin leads to receptor phosphorylation…
Also available at: PLOS
-
Journal Article
PD-1-stimulated T cell subsets are transcriptionally and functionally distinct
Summary: Despite the obvious inhibitory outcome of PD-1 signaling, an additional series of functions are activated. We have observed that T cells stimulated through the T cell receptor (TCR) and PD-1 primarily do not proliferate; however, there is a population of cells that proliferates more than…
-
Journal Article
Transmembrane adaptor protein PAG is a mediator of PD-1 inhibitory signaling in human T cells
Strazza et al. show that phosphoprotein associated with glycosphingolipidenriched microdomains 1 (PAG) is phosphorylated following PD-1 ligation. They find that PAG deletion sensitizes tumors to PD-1 blockade. This study suggests PAG as a critical mediator of PD-1 signaling and a promising target…
-
Journal Article
Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth
The transmembrane adaptor phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG) is phosphorylated in T cells downstream of PD-1 signaling and contributes to the resulting functional inhibition of multiple cellular processes. Furthermore, PAG expression is negatively…
-
Journal Article Full text
SLAMF6 clustering is required to augment T cell activation
The signaling lymphocytic activation molecule (SLAM) family is comprised of nine distinct receptors that are expressed exclusively on hematopoietic cells. Most of these transmembrane receptors are homotypic by nature and downstream signaling occurs when cells that express the same SLAM receptor…
Also available at: DOAJ
-
Journal Article
SLAMF6 compartmentalization enhances T cell functions
After stimulation, the T cell co-receptor SLAMF6 colocalizes with the TCR–CD3 complex to enhance T cell activation. Targeting SLAMF6 localization and function with bispecific antibodies is a novel mechanism with potential therapeutic translation. Signaling lymphocyte activation molecule family…
-
Journal Article
Case Report: Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome with flow cytometric phenotyping before and after treatment in a patient with urothelial carcinoma
Immune checkpoint inhibitor-associated myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) is an uncommon immune-related adverse event (irAE) associated with the use of immune checkpoint inhibitors for the treatment of malignancies. We present a case of a 77-year-old woman who…
-
Journal Article
PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis
Abstract Background PD-1 is an immune checkpoint on T cells, and interventions to block this receptor result in T cell activation and enhanced immune response to tumors and pathogens. Reciprocally, despite a decade of research, approaches to treat autoimmunity with PD-1 agonists have only had…
-
Journal Article
Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity
Background Immune checkpoint inhibitors (ICIs) have improved outcomes and extended patient survival in several tumor types. However, ICIs often induce immune-related adverse events (irAEs) that warrant therapy cessation, thereby limiting the overall effectiveness of this class of therapeutic…